NEUROMETA THERAPEUTICS
Pioneering neurometabolic medicine for neurodegenerative diseases
Neurometa Therapeutics (formerly 2N Pharma) is redefining the treatment of brain disorders by targeting the root cause: disrupted neuronal energy metabolism.
Traditional therapies focus on downstream protein pathologies. We go upstream, restoring the brain’s natural fuel balance to halt disease progression and deliver disease-modifying benefits.
Built on two decades of pioneering research by scientific founder Dr. John Nieland, proving neurons can oxidise fatty acids and that this process drives neurodegeneration, we’re advancing first-in-class small molecules to deliver meaningful, lasting benefits to those living with ALS and other devastating brain disorders.
2025 SERVIER Golden Ticket Winner: Selected through Servier’s partnership with SmiLe Venture Hub, Neurometa has secured lab space, mentorship, and resources to accelerate our mission from Lund.
Preben Bruun-Nyzell, the CEO of Neurometa Therapeutics spent the first 20 years of his career in international finance and was CFO of an industrial company with $2bn in annual sales and 1200 employees. In 2016 he became an accidental biotech entrepreneur, first as investor and board member of SmiLe company Apoglyx and later, when the biotech-bug had invaded all cells of his body, as co-founder of 2A Pharma, Geysir Therapeutics, and Neurometa Therapeutics.
Did you know?
Military veterans face nearly twice the risk of an ALS diagnosis compared to the general population. That’s why much of Neurometa Therapeutics’ work is funded by the United States Department of Defense. Our ALS therapeutics are dual-use innovations, serving the needs to military veterans and civilians alike.
